Comparison of interoperability among the standard systems of Chinese, the United States, European, and Japanese Pharmacopoeias and other standard systems

Published on Mar. 21, 2024Total Views: 2266 times Total Downloads: 675 times Download Mobile

Author: XU Xinyi ¹ LIU Zhen ² TAO Leran ³ SONG Haoyun ⁴ LI Dan ⁵ YU Wenli ⁶ WANG Guannan ⁷ LI Heng ⁸ WANG Yun ⁹  YANG Zhaopeng ¹

Affiliation: 1. Chinese Pharmacopoeia Commission, Beijing 100061, China 2. Jiangxi Institute for Drug Control, Nanchang 330029, China 3. School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China 4. National Institutes for Food and Drug Control, Beijing 102629, China 5. MSD Research and Development (China) Co., Ltd, Beijing 100012, China 6. Organon (Shanghai) Pharmaceutical Technology Co., Ltd, Shanghai 200030, China 7. Bayer Healthcare Co., Ltd, Beijing 100176, China 8. Merck Serrano (Beijing) Pharmaceutical Research and Development Co., Ltd, Beijing 100016, China 9. China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee, Beijing 100125, China

Keywords: Pharmacopoeia System Standard Interoperability Comparison

DOI: 10.12173/j.issn.1008-049X.202401151

Reference: XU Xinyi, LIU Zhen, TAO Leran, SONG Haoyun, LI Dan, YU Wenli,WANG Guannan, LI Heng, WANG Yun, YANG Zhaopeng.Comparison of interoperability among the standard systems of Chinese, the United States, European, and Japanese Pharmacopoeias and other standard systems[J].Zhongguo Yaoshi Zazhi,2023,26(12):233-241.DOI: 10.12173/j.issn.1008-049X.202401151.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To provide reference for the optimization and improvement of interoperability between the standard system of the Chinese Pharmacopoeia and other standards.

Methods The interoperability of various pharmacopoeia standard systems was compared by searching for citations from the Chinese Pharmacopoeia, the United States Pharmacopoeia-National Formulary, the European Pharmacopoeia, the Japanese Pharmacopoeia, and other standards, including references to domestic regulations and guidelines, standards of the International Organization for Standardization, guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, documents of the World Health Organization, and standards from other countries and international organizations.

Results In recent years, pharmacopoeias in the world had continuously increased the citation of non pharmacopoeial standards. The types, quantities, and fields of the United States Pharmacopoeia-National Formulary referencing other standards far exceed those of other pharmacopoeias. The Chinese Pharmacopoeia cites the least number of other standards.

Conclusion It is suggested that the Chinese Pharmacopoeia should enhance the interoperability with other standard systems in the standards of various professional fields, enhance the openness, harmonization and advantages, and form a more complete standard system.

Full-text

Please download the PDF version to read the full text: download

References

1.麦绿波. 《标准学》[M]. 北京: 科学出版社, 2022: 165.

2.张晓娟, 张梦田. 西方国家政府信息资源互操作性标准体系研究[J]. 情报资料工作，2015, (3): 42-48. [Zhang XJ, Zhang MT. Exploration of the western governments information resource interoperability standard system[J]. Information and Documentation Services, 2015, (3): 42-48.] DOI: CNKI:SUN:QBZL.0.2015-03-013.

3.王军华, 黄春荣, 谭清美. 军民融合技术标准互操作性实施研究[J]. 北京理工大学学报(社会科学版) , 2020, 22(4): 108-115. [Wang JH, Huang CR, Tan QM. Research on interoperability implementation of technical standards of military and civil convergence[J]. Journal of Beijing Institute of Technology (Social Sciences Edition), 2020, 22(4): 108-115.] DOI: 10.15918/j.jbitss1009-3370.2020.7483.

4.徐昕怡, 洪小栩. 各国药典核磁共振波谱法通则概况及其应用[J]. 药物流行病学杂志, 2023, 32(5): 564-574. [Xu XY, Hong XX. Overview and application of nuclear magnetic resonance spectroscopy method in pharmacopoeias[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(5): 564-574.] DOI: 10.19960/j.issn.1005-0698.202305011.

5.徐昕怡, 刘贞, 张震, 等. 中国药典片剂脆碎度检查法增修订回顾及与ICH协调的展望[J]. 中国药师, 2019, 22(6): 1138-1140. [Xu XY, Liu Z, Zhang Z, et al. Review of the Chinese Pharmacopoeia Tablet friability test revision history and prospects for harmoniza-tion with ICH[J]. China Pharmacist, 2019, 22(6): 1138-1140.] DOI: 10.3969/j.issn.1008-049X.2019.06.040.

6.耿颖, 宁保明, 陈华, 等. 中国药典通则与ICH Q4B有关含量均匀度检查判定法比较[J]. 中国药师，2022, 25(5): 878-883, 897. [Gen Y, Ning BM, Chen H, et al. Comparative evaluation of content uniformity between general chapter of Chinese Pharmacopoeia and ICH Q4B[J]. China Pharmacist, 2022, 25(5): 878-883, 897.] DOI: 10.19962/j.cnki.issn1008-049X.2022.05.023.

7.兰奋, 洪小栩, 宋宗华, 等. 《中国药典》2020年版基本概况和主要特点[J]. 中国药品标准, 2020, 21(3): 185-188. [Lan F, Hong XX, Song ZH, et al. Overview of the Chinese Pharmacopoeia 2020 edition[J]. Drug Standards of China, 2020, 21(3): 185-188.] DOI: 10.19778/j.chp.2020.03.001.

8.徐昕怡, 许华玉, 陈蕾, 等. 贯彻落实新发展理念编制好新时代新阶段《中国药典》[J]. 中国药品标准，2021, 22(5): 397-402. [Xu XY, Xu HY, Chen L, et al. Implementation of the new development philosophy and compilation of the Chinese Pharmacopoeia[J]. Drug Standards of China, 2021, 22(5): 397-402.] DOI: 10.19778/j.chp.2021.05.001.

9.中国药典2020年版. 一部[S]. 2020: 31902.

10.中国药典2020年版. 二部[S]. 2020: 31899.

11.中国药典2020年版. 三部[S]. 2020: 3703.

12.中国药典2020年版. 四部[S]. 2020: 1844.

13.USP现行版[S]. 2023.

14.EP 11.0 [S]. 2023: 14440.

15.JP 18 [S]. 2023: 12744.

16.沙明泉, 张亚伟, 周红洁, 等. 我国药品技术指导原则体系建设回顾与展望[J]. 中国药物警戒, 2022, 19(10): 1045-1049, 1059. [Sha MQ, Zhang YW, Zhou HJ, et al. A comparative progress and prospect for drug technological guidances system in China[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049, 1059.] DOI: 10.19803/j.1672-8629.20220351.

17.王波, 邵蓉. 论药品监管指导原则的法律渊源与法律运用[J]. 中国食品药品监管, 2022, (11)54-61. [Wang B, Shao R. Review on the Legal Source and Application of the NMPA's Guidelines on Drug Regulation[J]. China Food Drug Administration, 2022, (11)54-61.] DOI: 10.3969/j.issn.1673-5390.2022.11.005.